Anti-Saccharomyces Cerevisiae and Antineutrophil Cytoplasmic Antibodies As Predictors of Inflammatory Bowel Disease

Overview

Journal Gut

Specialty Gastroenterology

Date 2005 Aug 16

PMID 16099791

Citations 99

Authors

E Israeli

I Grotto

B Gilburd

R D Balicer

E Goldin

A Wiik

Y Shoenfeld

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Several antibodies have been reported in the sera of patients with Crohn's disease (CD) and ulcerative colitis (UC). The most commonly described are anti-Saccharomyces cerevisiae mannan antibodies (ASCA) in CD and perinuclear antineutrophil cytoplasm antibodies (pANCA) in UC. Familial clustering of these antibodies has been described, suggesting they might be genetic markers. Our aim was to investigate the presence of these antibodies before the emergence of overt clinical manifestations.

Methods: Since 1980, the Israeli Defense Force (IDF) Medical Corps Serum Repository has stored serum samples obtained systematically from 5% of all recruits on enlistment, and from the same population on discharge from compulsory military service. We evaluated serum samples obtained from 32 subjects with CD and eight with UC before they were clinically diagnosed, along with samples from matched controls.

Results: ASCA were present in 10/32 (31.3%) CD patients before clinical diagnosis compared with 0/95 (0%) controls (p<0.001). None of the eight patients with serum samples available before diagnosis of UC were ASCA positive. ASCA was positive in 54.5% of patients after diagnosis of CD. The mean interval between ASCA detection and diagnosis was 38 months. In 90% of patients, antibodies were detected in the first available serum sample; therefore, measurements of the average time from the presence of ASCA to diagnosis may be even longer. pANCA were present in 2/8 (25%) patients with available sera before the diagnosis of UC. None of their 24 matched controls were positive (p = 0.014).

Conclusions: ASCA and pANCA may predict development of inflammatory bowel disease years before the disease is clinically diagnosed.

Citing Articles

The Cell-Specific Effects of JAK1 Inhibitors in Ulcerative Colitis.

Veltkamp S, Voorneveld P J Clin Med. 2025; 14(2).

PMID: 39860613 PMC: 11766026. DOI: 10.3390/jcm14020608.

Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History.

Brunet-Mas E, Selva A, Bas-Cutrina F, Brujats A, Caballol B, Font R Clin Transl Gastroenterol. 2024; 16(2):e00740.

PMID: 39729123 PMC: 11845185. DOI: 10.14309/ctg.0000000000000740.

A unique serum IgG glycosylation signature predicts development of Crohn's disease and is associated with pathogenic antibodies to mannose glycan.

Gaifem J, Rodrigues C, Petralia F, Alves I, Leite-Gomes E, Cavadas B Nat Immunol. 2024; 25(9):1692-1703.

PMID: 39080486 PMC: 11362009. DOI: 10.1038/s41590-024-01916-8.

Bacteria: Potential Make-or-Break Determinants of Celiac Disease.

Roque A, Pereira S Int J Mol Sci. 2024; 25(4).

PMID: 38396767 PMC: 10889687. DOI: 10.3390/ijms25042090.

Investigating the shared genetic architecture between primary sclerosing cholangitis and inflammatory bowel diseases: a Mendelian randomization study.

Dong X, Gong L, Hong M, Pan J BMC Gastroenterol. 2024; 24(1):77.

PMID: 38373892 PMC: 10875759. DOI: 10.1186/s12876-024-03162-6.

References

Ruemmele F, Targan S, Levy G, Dubinsky M, Braun J, Seidman E . Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998; 115(4):822-9. DOI: 10.1016/s0016-5085(98)70252-5. View

Quinton J, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B . Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998; 42(6):788-91. PMC: 1727156. DOI: 10.1136/gut.42.6.788. View

Hoffenberg E, Fidanza S, Sauaia A . Serologic testing for inflammatory bowel disease. J Pediatr. 1999; 134(4):447-52. DOI: 10.1016/s0022-3476(99)70202-7. View

Macdermott R . Lack of current clinical value of serological testing in the evaluation of patients with IBD. Inflamm Bowel Dis. 1999; 5(1):64-5; discussion 66-7. DOI: 10.1097/00054725-199902000-00009. View

Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G . Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology. 1997; 113(3):802-7. DOI: 10.1016/s0016-5085(97)70174-4. View

Vasiliauskas E, Kam L, Karp L, Gaiennie J, Yang H, Targan S . Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000; 47(4):487-96. PMC: 1728065. DOI: 10.1136/gut.47.4.487. View

Reumaux D, Colombel J, Masy E, Duclos B, Heresbach D, Belaiche J . Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis. 2001; 6(4):270-4. DOI: 10.1002/ibd.3780060403. View

Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V . Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001; 7(1):8-15. DOI: 10.1097/00054725-200102000-00002. View

Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M . Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol. 2001; 36(2):196-201. DOI: 10.1080/003655201750065960. View

10.

Arbuckle M, James J, Kohlhase K, Rubertone M, Dennis G, Harley J . Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol. 2001; 54(1-2):211-9. DOI: 10.1046/j.1365-3083.2001.00959.x. View

11.

Annese V, Andreoli A, Andriulli A, DInca R, Gionchetti P, Latiano A . Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol. 2001; 96(8):2407-12. DOI: 10.1111/j.1572-0241.2001.04043.x. View

12.

Sandborn W, Loftus Jr E, Colombel J, Fleming K, Seibold F, Homburger H . Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001; 7(3):192-201. DOI: 10.1097/00054725-200108000-00003. View

13.

Secondulfo M, De Magistris L, Fiandra R, Caserta L, Belletta M, Tartaglione M . Intestinal permeability in Crohn's disease patients and their first degree relatives. Dig Liver Dis. 2002; 33(8):680-5. DOI: 10.1016/s1590-8658(01)80045-1. View

14.

Sostegni R, Daperno M, Ercole E, Rigazio C, Bresso F, Masoero G . Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker?. Dig Liver Dis. 2002; 33(9):755-61. DOI: 10.1016/s1590-8658(01)80692-7. View

15.

LaGasse J, Brantley M, Leech N, Rowe R, Monks S, Palmer J . Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care. 2002; 25(3):505-11. DOI: 10.2337/diacare.25.3.505. View

16.

Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, Colombel J . Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003; 17(1):19-35. DOI: 10.1053/bega.2002.0347. View

17.

Wiik A . Neutrophil-specific autoantibodies in chronic inflammatory bowel diseases. Autoimmun Rev. 2003; 1(1-2):67-72. DOI: 10.1016/s1568-9972(01)00007-6. View

18.

Arbuckle M, McClain M, Rubertone M, Scofield R, Dennis G, James J . Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349(16):1526-33. DOI: 10.1056/NEJMoa021933. View

19.

Nielen M, van Schaardenburg D, Reesink H, van de Stadt R, van der Horst-Bruinsma I, de Koning M . Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004; 50(2):380-6. DOI: 10.1002/art.20018. View

20.

Scofield R . Autoantibodies as predictors of disease. Lancet. 2004; 363(9420):1544-6. DOI: 10.1016/S0140-6736(04)16154-0. View